Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New interview with Dr Coffey

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Nov 16, 2022 11:37am

263 Views

Post# 35103465

RE:RE:RE:New interview with Dr Coffey

We should all recall the quarterly conferemce call when the first half results were announced. The BD guy said very clearly and definitely that we were at that point "in discussions" with multiple bp companies in multiple indications.

That would seem to be about as much as they can say without running afoul of disclosure rules.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand